ArticleThe Korean journal of internal medicine2019
Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease.
Article in The Korean journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00860431 (K-STAR), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
K-STAR (Kremezin STudy Against Renal Disease Progression in Korea) Randomized, Open-label, Controlled Study
Who cites it
17 citing papers in PubMed.
- Cardiovascular risk assessed using the SCORE system and blood renalase concentration in the Polish subpopulation of the PURE study.Scientific reports · 2026Article
- Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients.BMC nephrology · 2025Article
- Review
- Renalase: a novel regulator of cardiometabolic and renal diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Article
- Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature.The Journal of international medical research · 2021Review
- Blood pressure control in patients with chronic kidney disease.The Korean journal of internal medicine · 2021Review
- The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients.International journal of environmental research and public health · 2021Article
- Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study.Life (Basel, Switzerland) · 2021Article
- Renalase in Haemodialysis Patients with Chronic Kidney Disease.Journal of clinical medicine · 2021Article
- The Discriminatory Ability of Renalase and Biomarkers of Cardiac Remodeling for the Prediction of Ischemia in Chronic Heart Failure Patients With the Regard to the Ejection Fraction.Frontiers in cardiovascular medicine · 2021Article
- The clinical impact of gut microbiota in chronic kidney disease.The Korean journal of internal medicine · 2020Review
- Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients.BMC nephrology · 2020Article
- Ameliorative effect of sesamin in cisplatin-induced nephrotoxicity in rats by suppressing inflammation, oxidative/nitrosative stress, and cellular damage.Physiological research · 2020Article
- Association of Plasma Renalase and Left Ventricle Mass Index in Heart Failure Patients Stratified to the Category of the Ejection Fraction: A Pilot Study.Disease markers · 2019Article
- Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention.Journal of clinical medicine · 2018Article
- Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsPatients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431).
methodsA retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes.
resultsThe mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD.
conclusionOur results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.